Assessing Global Invasion of Newly Diagnosed Glial Tumors with Whole-Brain Proton MR Spectroscopy

References

1. ↵
   DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114–123

   CrossRefPubMedWeb of Science
2. ↵
   Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neurooncol 1999;1:14–25

   Abstract/FREE Full Text
3. ↵
   Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624–1636

   Abstract/FREE Full Text
4. ↵
   Loeffler JS, Alexander E 3rd, Hochberg FH, et al. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 1990;19:1455–1462

   PubMed
5. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992;24:55–57

   CrossRefPubMedWeb of Science
6. ↵
   Heros DO, Renkens K, Kasdon DL, Adelman LS. Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases. Neurosurgery 1988;22:474–478

   PubMed
7. ↵
   Lunsford LD, Martinez AJ, Latchaw RE. Magnetic resonance imaging does not define tumor boundaries. Acta Radiol Suppl 1986;369:154–156

   PubMed
8. ↵
   Kaplan WD, Takvorian T, Morris JH, et al. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 1987;28:47–52

   Abstract/FREE Full Text
9. Black KL, Hawkins RA, et al. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 1989;71:342–346

   PubMedWeb of Science
10. ↵
    Kim KT, Black KL, Marciano D, et al. Thallium-201 SPECT imaging of brain tumors: methods and results. J Nucl Med 1990;31:965–969

    Abstract/FREE Full Text
11. ↵
    Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

    PubMedWeb of Science
12. Aronen HJ, Glass J, Pardo FS, et al. Echo-planar MR cerebral blood volume mapping of gliomas: clinical utility. Acta Radiol 1995;36:520–528

    PubMed
13. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2‐weighted MR imaging. Radiology 1999;211:791–798

    CrossRefPubMedWeb of Science
14. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881–890

    Abstract/FREE Full Text
15. ↵
    Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
16. ↵
    Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000;2:166–189

    CrossRefPubMedWeb of Science
17. ↵
    Graves EE, Nelson SJ, Vigneron DB, et al. A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurgery 2000;46:319–326; discussion 326–318

    CrossRefPubMed
18. ↵
    Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37–45

    CrossRefPubMedWeb of Science
19. ↵
    Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995;46:531–540

    CrossRefPubMedWeb of Science
20. ↵
    Gonen O, Viswanathan AK, Catalaa I, et al. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 2998;40:684–689
21. ↵
    Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15–19

    Abstract/FREE Full Text
22. ↵
    Movsas B, Li BS, Babb JS, et al. Quantifying radiation therapy-induced brain injury with whole-brain proton MR spectroscopy: initial observations. Radiology 2001;221:327–331

    CrossRefPubMedWeb of Science
23. ↵
    De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529–539

    CrossRefPubMedWeb of Science
24. ↵
    Soher BJ, van Zijl PC, Duyn JH, Barker PB. Quantitative proton MR spectroscopic imaging of the human brain. Magn Reson Med 1996;35:356–363

    PubMedWeb of Science
25. ↵
    Kelly PJ, Daumas-Duport C, Kispert DB, et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865–874

    CrossRefPubMedWeb of Science
26. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol 1997;34:85–101

    CrossRefPubMed
27. Kelly PJ, Earnest FT, Kall BA, et al. Surgical options for patients with deep-seated brain tumors: computer-assisted stereotactic biopsy. Mayo Clin Proc 1985;60:223–229

    PubMed
28. ↵
    Kelly PJ, Kall BA, Goerss S, Earnest FT. Computer-assisted stereotaxic laser resection of intra-axial brain neoplasms. J Neurosurg 1986;64:427–439

    PubMed
29. ↵
    Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450–459

    CrossRefPubMedWeb of Science
30. ↵
    Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635–1642

    Abstract/FREE Full Text
31. ↵
    Cummings TJ, Hulette CM, Longee DC, et al. Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. Clin Neuropathol 1999;18:190–197

    PubMed
32. ↵
    Lantos PL, Pilkington GJ. Neuronal changes in experimental gliomas. Neuropathol Appl Neurobiol 1980;6:255–266

    PubMed
33. Takano T, Lin JH, Arcuino G, et al. Glutamate release promotes growth of malignant gliomas. Nat Med 2001;7:1010–1015

    CrossRefPubMedWeb of Science
34. Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999;59:4383–4391

    Abstract/FREE Full Text
35. ↵
    Van Meir E, Sawamura Y, Diserens AC, et al. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 1990;50:6683–6688

    Abstract/FREE Full Text
36. ↵
    Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433–437

    Abstract/FREE Full Text
37. ↵
    Earnest FT, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823–827

    PubMedWeb of Science
38. ↵
    Daumas-Duport C, Scheithauer BW, Chodkiewicz JP, et al. Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures: report of thirty-nine cases. Neurosurgery 1988;23:545–556

    PubMedWeb of Science
39. ↵
    Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704–710

    Abstract/FREE Full Text
40. ↵
    Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999;91:1382–1390

    Abstract/FREE Full Text
41. ↵
    Gonen O, Wang ZJ, Viswanathan AK, et al. Three-dimensional multivoxel proton MR spectroscopy of the brain in children with neurofibromatosis type 1. AJNR Am J Neuroradiol 1999;20:1333–1341

    Abstract/FREE Full Text
42. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001;22:604–612

    Abstract/FREE Full Text
43. ↵
    Stadlbauer A, Moser E, Gruber S, et al. Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas. Neuroimage 2004;23:454–461

    PubMed
44. ↵
    Brainard JA, Prayson RA, Barnett GH. Frozen section evaluation of stereotactic brain biopsies: diagnostic yield at the stereotactic target position in 188 cases. Arch Pathol Lab Med 1997;121:481–484

    PubMed
45. ↵
    Hall WA. The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 1998;82:1749–1755

    CrossRefPubMedWeb of Science
46. ↵
    Fine HA. Novel biologic therapies for malignant gliomas: antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin 1995;13:827–846

    PubMed